ANRO•benzinga•
Alto Neuroscience shares are trading higher after the company announced interim analysis results from its Phase 2b trial of ALTO-300.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 12, 2025 by benzinga